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Objective:  To  elucidate  the  current  status  of use of  inferior  vena  cava  ﬁlters  (IVCFs)  in  cases  of  pulmonary
embolism  at institutions  belonging  to  the  Tokyo  CCU  Network.
Methods:  We  conducted  a retrospective  investigation  of  832  consecutive  cases of  pulmonary  embolism
reported  on  survey  forms  to the  Tokyo  CCU  Network  between  2005  and  2010.
Results: Of  832  cases  of  pulmonary  embolism,  IVCFs  were  used  in 338  (40.6%)  and not  used  in  415 (49.9%).
Their  use was  unclear  in  79  (9.5%)  cases.  The  use rate gradually  increased  each  year  from  2005  until  2008
but  decreased  from  2009  onward.  Moreover,  68.9%  of the  IVCFs  used  in  cases  were  non-permanent
types.  In terms  of pulmonary  embolism  severity,  the  rate  of  use  was  37.2%  in  non-massive  cases,  49.4%
in sub-massive  cases,  46.9%  in massive  cases,  and  31.9%  in  collapse  cases.  Thirty-day  mortality  in  cases
of  collapse  in which  IVCFs  were  not  used  was extremely  high  at 75.8%,  suggesting  that  in many  cases,
rapid  deterioration  may  occur with  insufﬁcient  time  for IVCF  insertion.  The  differences  in  IVCF  usage  rate
among  institutions  were  large  in  the range  of  12.5–90%  from  2005  to 2008,  which  slightly  declined  to the
range  of 25.0–72.2%  from  2009  to 2010.
Conclusions:  We  elucidated  the  current  IVCF use  status  in  cases  of pulmonary  embolism  at  institutions
belonging  to the Tokyo  CCU  Network.  Since  the  status  of  use  differed  among  institutions,  future  studies
se  are
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Pulmonary embolism causes circulatory disturbances due to
bstruction of the pulmonary artery, and possible obstructions
nclude clots, air, fat, and tumors, although embolization is caused
y deep vein thrombosis in the legs or pelvis in >90% of cases. Acute
ulmonary embolism is increasing in Japan and mortality rates are
urrently 14% [1,2], so there is public demand for the appropriate
anagement of pulmonary embolism.
“The Guidelines for the Prevention of Pulmonary Thromboem-
olism/Deep Vein Thrombosis” were produced for the ﬁrst time
n Japan in 2004 [3]. In 2009, the Japanese Circulation Society pub-
ished the “Guidelines for the Diagnosis, Treatment, and Prevention
f Pulmonary Thromboembolism and Deep Vein Thrombosis (2009
evised edition)” [4]. According to these guidelines, standard
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ax: +81 03 3446 7381.
E-mail address: y-tanabe@muj.biglobe.ne.jp (Y. Tanabe).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.10.003 required.
anese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
treatment focuses on physical therapies such as early ambulation,
elastic stockings, and intermittent pneumatic compression with
the combined use of anticoagulant therapy for high-risk patients,
and these treatments that prevent pulmonary embolism are cur-
rently covered by health insurance. The synthetic Xa inhibitor
fondaparinux, which was formerly covered by health insurance
only for the preventive application to high-risk patients in the peri-
operative period, has also been approved for the treatment of deep
vein thrombosis since March 2011. The prevention and treatment
of venous thrombosis is thus making strides and public awareness
of it is also high. Despite this, the number of cases of deep venous
thrombosis shows no sign of declining. Measures to prevent seri-
ous pulmonary embolism when deep venous thrombosis occurs are
therefore required.
Inferior vena cava ﬁlters (IVCFs) are considered effective devices
for preventing the occurrence/recurrence of pulmonary throm-
boembolism by preventing deep vein thrombosis from entering
the pulmonary artery after it has become detached. However, their
effectiveness has only been investigated in a single randomized
trial, the PREPIC Study [5], and the evidence is still insufﬁcient. The
only multicenter survey of their status of use in Japan was that
vier Ltd. All rights reserved.
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Unknown 1.5%  (5)
Fig. 1. (1) Inferior vena cava ﬁlters were used in 338 (40.6%), not used in 415 (49.9%),86 Y. Tanabe et al. / Journal o
f Yamada et al. [6], which dates back to 2001, before the use of
etrievable IVCFs became widespread, and the current situation is
nvisaged to be different.
The objective of this study was to elucidate the current status
f IVCF use in cases of pulmonary embolism at cardiac care units
CCUs) in 62 institutions belonging to the Tokyo CCU Network.
aterials and methods
The study was performed using data from the Tokyo CCU Net-
ork. The Tokyo CCU Network is operated through 62 hospitals
ith the help of ambulance units through the control room of the
okyo Fire Department. Institutions belonging to the Tokyo CCU
etwork routinely record and submit details of all patients treated
n their CCUs on survey forms [1]. In this study, subjects comprised
 continuous series of 832 cases (350 males, 482 females; average
ge, 64.5 ± 16.0 years) treated at institutions belonging to the Tokyo
CU Network between January 2005 and December 2010, and the
se of IVCFs was evaluated on the basis of these survey forms.
Seven hospitals that treated a large number of cases of pul-
onary embolism were asked to complete an additional survey
egarding the presence or absence of deep vein thrombosis and the
tatus of IVCF use.
Statistical comparisons of continuous variables were per-
orming using Student’s t-test or the Mann–Whitney U test as
ppropriate. Statistical comparisons of dichotomous variables were
arried out using the chi-squared test. The values of p < 0.05 were
onsidered statistically signiﬁcant.
esults
tatus of IVCF use
IVCFs were used in 40.6% (338 cases) of the total 832 cases of
ulmonary embolism treated in CCUs (Fig. 1-1).
hanges over time in IVCF use rate
The IVCF use rate gradually increased from 45.0% in 2005 to
2.3% in 2008 and then reversed and fell to 37.1% in 2009 and
4.1% in 2010. This is an extremely noteworthy trend that will be
iscussed further below (Fig. 1-2).
VCF types used
Non-permanent IVCFs accounted for the majority, 68.9%. Since
he survey forms used from 2005 until early 2009 made no dis-
inction between retrievable ﬁlters and temporary ﬁlters among
he non-permanent ﬁlters, it is unclear which type was  used more
ften. Therefore, we revised the survey form to make this distinc-
ion after mid-2009 (Fig. 1-3).
tate of IVCF use by pulmonary embolism severity
The pulmonary embolism severity among these 832 cases was
lassiﬁed as non-massive (no signs of right heart load) in 331 cases
39.8%), sub-massive (right heart load present but no shock) in 261
31.4%), massive (right heart load and shock) in 81 (9.7%), and col-
apse (cardiopulmonary arrest, pulseless electric activity or other
irculatory collapse) in 47 (5.6%). The IVCF used in each category
as then evaluated (although severity was unknown in 79 cases).
s shown in Fig. 2, the use rate increased in the order of non-
assive (37.2%) < sub-massive (49.4%), and massive (46.9%), but it
as low in cases of collapse (31.9%).and unknown in 79 (9.5%) cases. (2) The use rate gradually increased from 2005 to
2008 and decreased after 2009. (3) Non-permanent inferior vena cava ﬁlters were
used in 68.9% of cases.
Relationship between IVCF use by severity and acute mortalityThirty-day mortality in cases of collapse in which IVCFs were
not used was high at 75.8%, and it was  signiﬁcantly higher than
that of patients for whom IVCFs were used (20.0%) (p = 0.0009). The
Y. Tanabe et al. / Journal of Cardiology 63 (2014) 385–389 387
Fig. 2. Considering acute pulmonary embolism severity, inferior vena cava ﬁlter use
rates were 37.2% in non-massive cases, 49.4% in sub-massive cases, 46.9% in massive
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Non-Use
46.7%
Unknown 2.8%
Use
30.2%
Non-Use
53.2%
Unknown16.6%
P<0.01ases, and 31.9% in collapse cases.
ortality rate in sub-massive and massive cases in which IVCFs
ere used was also in a lower trend than that in patients in whom
hey were not used (2.3% versus 4.1% in sub-massive, 21.1% versus
6.6% in massive, respectively) (Table 1).
ifference of usage rate by performing thrombolytic therapy
The difference in IVCF use rate in the cases of whether throm-
olytic therapy was performed or not was analyzed. The IVCF use
ate was signiﬁcantly higher in the patients with thrombolysis than
n the patients without thrombolysis (Fig. 3).
ifferences between institutions in status of IVCF use
Seven institutions that treated a large number of cases of pul-
onary embolism were asked to complete an additional survey
n deep vein thrombosis and IVCF use status, and the differences
n use between these institutions were then evaluated. The rate
f IVCF use between 2005 and 2008 varied greatly, ranging from
2.5% at S Hospital to 90% at M Hospital (Fig. 4-1). The rate of use
n each institution before and after 2009, when the overall use rate
urned downward, was then investigated. As shown in Fig. 4-2, the
se rate fell at M Hospital and N Hospital, where it had been high
efore 2009, and rose at F Hospital and S Hospital, where it had been
ow. Overall the differences in IVCF usage rate among institutions
ere large; however it tended to decline after 2009.
able 1
hirty-day mortality in cases of collapse in which IVCFs were not used was  high at
5.8%, and it was  signiﬁcantly higher than that of patients for whom IVCFs were
sed (20.0%) (p = 0.0009). The mortality rate in sub-massive and massive cases in
hich IVCFs were used also in a lower trend than that in they were not used.
30 days mortality
Non-
massive
IVCF(+) 2.4% (3/123)
p = 0.91
IVCF(−) 2.0% (4/202)
Sub-
massive
IVCF(+) 2.3% (3/129)
p = 0.43
IVCF(−) 4.1% (5/123)
Massive
IVCF(+) 21.1% (8/38)
p = 0.20
IVCF(−) 36.6% (15/41)
Collapse
IVCF(+) 20.0% (3/15)
p = 0.0009
IVCF(−) 75.8% (22/29)Fig. 3. The inferior vena cava ﬁlter use rate of the patients undergoing thrombolytic
therapy was  signiﬁcantly higher than that of the patients without thrombolytic
therapy.
Discussion
There have been few large clinical studies concerning acute pul-
monary embolism in Japan since the incidence of acute pulmonary
embolism is relatively low compared to the western countries [4,7]
and many hospitals treat pulmonary embolism in the Japanese
medical system and the cases of each hospital are too small to
analyze. This study is meaningful by investigating 832 cases and
providing information of the current status of the IVCFs in a
metropolitan city of Japan.
In this survey, we  found that IVCFs were used in 40.6% of cases
of pulmonary embolism treated in CCUs at institutions belonging
to the Tokyo CCU Network; of these, 68.9% were non-permanent
types. The PREPIC Study [5], the sole randomized trial of IVCFs,
reported that permanent IVCFs were effective in preventing pul-
monary embolism during the acute phase, but that the recurrence
rate of deep vein thrombosis in the legs increased signiﬁcantly
in the chronic phase. For this reason, it is recommended that ﬁl-
ters not be inserted without aim, be used in patients in whom
the risk of pulmonary embolism has been reduced by thrombolysis
and anticoagulant therapy in the acute phase, be used only in the
acute phase, and not be left permanently in place [7]. Our survey
revealed that non-permanent IVCFs were used in 68.9% of cases,
and the result suggested that they were used only during the acute
phase. However, because the forms used in this survey made no
distinction between retrievable ﬁlters and temporary ﬁlters among
non-permanent ﬁlters and the retrieval rate of the retrievable ﬁl-
ters is also unknown, an accurate assessment of the situation is
currently impossible. These points were added to the new survey
forms that came into use in 2009 and available on survey at present;
therefore, we intend to investigate these issues in the future.
Serial change of IVCF use
The IVCF use rate gradually increased each year from 2005,
when the survey began, until 2008 and then began to decrease in
2009, an interesting trend. Non-permanent IVCFs rapidly achieved
widespread use in Japan due to their simplicity, but their reported
complications included migration, fracture, infection, and perfo-
ration of the venous wall [8–11]. Warnings were issued in August
2010 by the US Federal Drug Administration and in December 2010
by the Japanese Ministry of Health, Labor and Welfare that indica-
tions for their insertion should be stringently evaluated and that
they should be retrieved as often as possible, with long-term inser-
tion to be avoided. In light of these warnings, IVCF removal has been
covered by health insurance since April 2012. The decreased IVCF
388 Y. Tanabe et al. / Journal of Cardiology 63 (2014) 385–389
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sig. 4. (1) The usage rates of inferior vena cava ﬁlters (IVCFs) varied in the range o
fter  2009.
se rate in 2009 seen in our survey suggests that institutions of the
okyo CCU Network already used them on the basis of stringent
ndications in advance of these warnings.
ifference of IVCF use rate by performing thrombolytic therapy
The IVCF use rate was signiﬁcantly higher in patients with
hrombolysis than in patients without thrombolysis. We  consider
hat the higher rate of the patients with thrombolysis was due to the
act that the indication of tissue plasminogen activator thrombo-
ysis in Japan was  deﬁned to be for the hemodynamically unstable
cute pulmonary embolism with right heart overload. In such cases
f the deep vein thrombi ﬂoated by thrombolysis and embolized to
ulmonary artery recurrently, it produced catastrophic hemody-
amic deterioration, so the IVCFs were used in many cases with
hrombolytic therapy.
nstitution difference of IVCF use
Our evaluation of the IVCF use rate in different institutions found
hat between 2005 and 2008 there was a great variation between
nstitutions in the range of 12.5–90%. After 2009, their use declined
n institutions that had previously had an extremely high use rate
nd increased in those in which it had previously been at a low rate;
owever, despite this narrowing of the gap, the difference between
nstitutions remained large. Problems with our survey include the
acts that (a) although it covered all patients, the response rate
as not necessarily high, and (b) there may  have been differences
n CCU systems and the severity of patients managed in CCUs in
he different institutions. Even when these points are taken into
ccount, however, our results still indicate that IVCF use differs
etween institutions. Indications for IVCF use are detailed in both
he Japanese Circulation Society guidelines [4] and non-Japanese
uidelines [12]. Their use is absolutely indicated in cases of deep
ein thrombosis in which anticoagulant therapy is contraindicated
nd in cases of recurrent pulmonary embolism despite adequate
nticoagulant therapy. In this regard, no difference among insti-
utions of the CCU Network is considered on this point. Their use
s relatively indicated in cases of free-ﬂoating proximal deep vein
hromboses that are highly likely to cause pulmonary embolism.
The difference among institutions in IVCF use is probably due
o differences in their evaluations of whether venous thrombi are
ree-ﬂoating and of the pulmonary embolism recurrence risk. At H
ospital, the authors’ hospital, when retrievable IVCFs ﬁrst came
nto use, they were used in many cases of deep vein thrombo-
is due to their simplicity and safety. Although these ﬁlters were90% among the institutions. (2) Changes in use rate at each institution before and
considered to effectively prevent pulmonary embolisms, they did
not capture any thrombi in some patients; in a few other cases, they
could not be retrieved, perforated the venous wall, or migrated from
their positions. For this reason, we have recently been determin-
ing whether their use is indicated based on an overall evaluation
that includes clinical symptoms, contrast computed tomography,
venous ultrasound, and blood D-dimer level. In other countries as
well, concern has been expressed about increasingly widespread
IVCF use [13].
IVCF use and acute mortality
In terms of the relationship between pulmonary embolism
severity and IVCF use, although the use rate increased with
increasing severity in the order of non-massive < sub-massive, and
massive, it decreased in reverse in the most severe cases involving
collapse. Thirty-day mortality in cases of collapse was extremely
high (75.8%) in patients in whom IVCFs were not used compared
with 20.0% for those in whom they were used. Of  47 collapse cases,
IVCFs were used in 15 cases, not used in 29 cases, and unknown in
3 cases. A total of 3 of 15 (20%) cases with IVCFs died, the causes
of death were one cardiogenic shock and two  recurrent pulmonary
embolisms. Whereas 22 of 29 (75.2%) cases without IVCFs died, the
causes of death were 13 cardiogenic shock, 4 recurrent pulmonary
embolism, 3 multiple organ failure, 1 heart failure, and 1 unknown
cause. Then we evaluated the vital signs at the ﬁrst contacts, we
found that the blood pressures and SpO2 were similar between the
groups. The causes of death and the vital signs at the ﬁrst contact
were similar between the groups, however, the severity appeared
to be different. All 3 fatal cases with IVCFs passed away more than
48 h after admission, whereas 18 of 22 (81.8%) cases without IVCFs
passed away in 48 h after admission, in particular 14 of 22 (63.6%)
within 24 h. Considering the IVCF is not a device for treating pul-
monary embolism itself but for preventing recurrence, this fact
indicated that many patients might have died because the rapid
deterioration of their condition left no time for the evaluation of
deep vein thrombosis or IVCF insertion. Therefore, there were some
biases for selection of IVCF which might affect the mortality rate in
this study.
Concerning the massive cases, Kucher et al. reported IVCFs were
associated with a reduction in 90-day mortality in 108 consecutive
patients with massive pulmonary embolism [14]. In this study, the
30-day mortality rate of the IVCF use group was  also lower than that
of the IVCF non-use group in the massive and sub-massive cases.
Since sub-massive pulmonary embolism itself is not fatal, this fact
might suggest IVCF’s effect of protecting patients from recurrent
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ulmonary embolism. We  do not have sufﬁcient data to prove this
ffect at present, we intend to collect and analyze detailed data
oncerning the mortality of the sub-massive cases in the future.
tudy limitations and future resolution
First, the limitation of this study is due to prospective cohort
nalysis, that our survey was not sufﬁciently detailed with respect
o methods of evaluating deep vein thrombosis at different insti-
utions and investigating what ﬁndings are considered indications
or IVCF use in each institution.
Second, blood examinations were completely outside of evalua-
ion in this study since the data about blood examinations were not
btained by the former survey forms. Several studies showed that
ardiac biomarkers such as serum troponin and B-type natriuretic
eptide and the blood glucose level were good indicators of severity
nd mortality of acute pulmonary embolism [15–18]. Information
bout blood examinations was added to the survey form from 2009,
herefore, we intend to investigate the relationship among cardiac
iomarkers, severity of pulmonary embolism, and IVCF usage in the
uture.
onclusions
In this study, we elucidated the current status of IVCF use in
ases of pulmonary embolism at institutions belonging to the Tokyo
CU Network. Further study is required to determine the types of
ases in which IVCFs should be used in the standard treatment for
ulmonary embolism in CCUs.
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